Xenon Pharmaceuticals Inc.

XENESEC EDGAR

Pharmaceutical Preparations(A1)CIK: 1582313

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	—	—
Research and Development Expense	$167.5M	$105.8M	$75.5M	$50.5M	$50.5M
Operating Expenses	$214.1M	$138.6M	$97.4M	$63.5M	$63.5M
Operating Income (Loss)	-$214.1M	-$129.1M	-$79.0M	-$31.3M	-$31.3M
Interest Expense	—	—	—	$484.0K	$484.0K
Nonoperating Income (Expense)	$31.4M	$3.9M	$105.0K	$2.2M	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$182.7M	-$125.3M	-$78.9M	-$29.1M	-$29.1M
Income Tax Expense (Benefit)	-$292.0K	$118.0K	-$6.0K	-$257.0K	-$257.0K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$798.1M	$964.8M	$754.1M	$572.0M	$189.2M
Assets, Current	$635.3M	$645.0M	$600.3M	$559.0M	$181.8M
Cash and Cash Equivalents, at Carrying Value	$142.7M	$148.6M	$57.2M	$175.7M	$45.0M
Accounts Receivable, after Allowance for Credit Loss, Current	—	$874.0K	$986.0K	$2.8M	$1.8M
Liabilities	$43.2M	$36.9M	$32.6M	$22.0M	$17.8M
Liabilities, Current	$35.6M	$27.3M	$22.7M	$14.3M	$14.8M
Long-term Debt, Excluding Current Maturities	—	—	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$151.1M	-$101.0M	-$69.5M	-$48.1M	-$48.1M
Net Cash Provided by (Used in) Investing Activities	-$111.4M	-$293.4M	-$246.8M	-$16.8M	-$16.8M
Net Cash Provided by (Used in) Financing Activities	$353.5M	$278.5M	$447.5M	$85.8M	$85.8M
Payments to Acquire Property, Plant, and Equipment	$5.6M	$2.9M	$2.0M	$2.6M	$2.6M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)